Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy.
The reverse transcriptase V207I mutation within the hepatitis B virus (HBV) polymerase is associated with resistance to lamivudine in vitro. The prevalence of this mutation in treatment-naive patients was 1% (1/96). A follow-up of the patient carrying this mutation prior to treatment revealed no loss of sensitivity of HBV to lamivudine in vivo.
Zöllner
B
B
Institute for Infectious Diseases, University Hospital Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany. zoellner@uke.uni-hamburg.de
Sterneck
M
M
Wursthorn
K
K
Petersen
J
J
Schröter
M
M
Laufs
R
R
Feucht
H-H
HH
D000595:Amino Acid Sequence; D019943:Amino Acid Substitution; D000998:Antiviral Agents / Q000627:therapeutic use; D004279:DNA, Viral / Q000097:blood; D024882:Drug Resistance, Viral; D006509:Hepatitis B / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000187:drug effects / Q000201:enzymology / Q000235:genetics*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use; D012194:RNA-Directed DNA Polymerase / Q000235:genetics*; D011994:Recombinant Proteins
D000998:Antiviral Agents; D004279:DNA, Viral; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D019259:Lamivudine; D011092:Polyethylene Glycols; D012194:RNA-Directed DNA Polymerase; C100416:peginterferon alfa-2a